ArticleAntimicrobial agents and chemotherapy2010
Molecular characterization of off-target activities of telithromycin: a potential role for nicotinic acetylcholine receptors.
Article in Antimicrobial agents and chemotherapy, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 73 citations in OpenAlex.
- Randomized, double-blind, multicenter phase 2 study comparing the efficacy and safety of oral solithromycin (CEM-101) to those of oral levofloxacin in the treatment of patients with community-acquired bacterial pneumonia.Antimicrobial agents and chemotherapy · 2013Trial
- Cethromycin versus clarithromycin for community-acquired pneumonia: comparative efficacy and safety outcomes from two double-blinded, randomized, parallel-group, multicenter, multinational noninferiority studies.Antimicrobial agents and chemotherapy · 2012Trial
- Pharmacokinetics of solithromycin (CEM-101) after single or multiple oral doses and effects of food on single-dose bioavailability in healthy adult subjects.Antimicrobial agents and chemotherapy · 2011Trial
- Nicotinic acetylcholine receptors in pain modulation.Frontiers in pharmacology · 2026Review
- Unraveling the therapeutic landscape of approved non-peptide macrocycles.Acta pharmaceutica Sinica. B · 2025Review
- Analyzing the Mechanisms Behind Macrolide Antibiotic-Induced Liver Injury Using Quantitative Systems Toxicology Modeling.Pharmaceutical research · 2019Article
- Ribosome-Targeting Antibiotics: Modes of Action, Mechanisms of Resistance, and Implications for Drug Design.Annual review of biochemistry · 2018Review
- Natural Products as Platforms To Overcome Antibiotic Resistance.Chemical reviews · 2017Review
- Activity-based protein profiling reveals off-target proteins of the FAAH inhibitor BIA 10-2474.Science (New York, N.Y.) · 2017Article
- Neuropsychiatric Effects of Antimicrobial Agents.Clinical drug investigation · 2017Review
- Nature nurtures the design of new semi-synthetic macrolide antibiotics.The Journal of antibiotics · 2017Review
- Spotlight on solithromycin in the treatment of community-acquired bacterial pneumonia: design, development, and potential place in therapy.Drug design, development and therapy · 2017Review
- Solithromycin: A Novel Fluoroketolide for the Treatment of Community-Acquired Bacterial Pneumonia.Drugs · 2016Review
- Targeting Antibiotic Resistance.Angewandte Chemie (International ed. in English) · 2016Review
- Antibiotic-induced neurotoxicity.Current infectious disease reports · 2014Article
- The evolving role of chemical synthesis in antibacterial drug discovery.Angewandte Chemie (International ed. in English) · 2014Review
- A novel ketolide, RBx 14255, with activity against multidrug-resistant Streptococcus pneumoniae.Antimicrobial agents and chemotherapy · 2014Article
- Maternal administration of solithromycin, a new, potent, broad-spectrum fluoroketolide antibiotic, achieves fetal and intra-amniotic antimicrobial protection in a pregnant sheep model.Antimicrobial agents and chemotherapy · 2014Article
- Investigational antimicrobial agents of 2013.Clinical microbiology reviews · 2013Review
- A novel macrolide/fluoroketolide, solithromycin (CEM-101), reverses corticosteroid insensitivity via phosphoinositide 3-kinase pathway inhibition.British journal of pharmacology · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Adverse effects have limited the clinical use of telithromycin. Preferential inhibition of the nicotinic acetylcholine receptors (nAChR) at the neuromuscular junction (α3β2 and NMJ), the ciliary ganglion of the eye (α3β4 and α7), and the vagus nerve innervating the liver (α7) could account for the exacerbation of myasthenia gravis, the visual disturbance, and the liver failure seen with telithromycin use. The studies presented here enable the prediction of expected side effects of macrolides in development, such as solithromycin (CEM-101).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.